{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:51:52Z","timestamp":1791478312068,"version":"4.3.4"},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,6,29]],"date-time":"2024-06-29T00:00:00Z","timestamp":1719619200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,29]],"date-time":"2024-06-29T00:00:00Z","timestamp":1719619200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81970340"],"award-info":[{"award-number":["81970340"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82000372"],"award-info":[{"award-number":["82000372"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170384"],"award-info":[{"award-number":["82170384"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82270399"],"award-info":[{"award-number":["82270399"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2022A1515012161"],"award-info":[{"award-number":["2022A1515012161"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2023A1515011794"],"award-info":[{"award-number":["2023A1515011794"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Key R&D Projects of Guangzhou Science and Technology Program","award":["2023B03J1243"],"award-info":[{"award-number":["2023B03J1243"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s10557-024-07587-9","type":"journal-article","created":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T17:01:45Z","timestamp":1719853305000},"page":"1465-1480","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Early Management of Blood Lipid Levels with Non-Statin Lipid-Lowering Drugs in Acute Coronary Syndrome: A Mini Review"],"prefix":"10.1007","volume":"39","author":[{"given":"Chen","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang-Fei","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yugang","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9818-0454","authenticated-orcid":false,"given":"Chen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,29]]},"reference":[{"issue":"10","key":"7587_CR1","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/S0025-6196(11)60509-0","volume":"84","author":"A Kumar","year":"2009","unstructured":"Kumar A, Cannon CP. Acute coronary syndromes: diagnosis and management, part I. Mayo Clin Proc. 2009;84(10):917\u201338. https:\/\/doi.org\/10.1016\/S0025-6196(11)60509-0.","journal-title":"Mayo Clin Proc."},{"issue":"20","key":"7587_CR2","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1161\/CIRCULATIONAHA.117.030798","volume":"136","author":"E Puymirat","year":"2017","unstructured":"Puymirat E, Simon T, Cayla G, et al. Acute myocardial infarction: changes in patient characteristics, management, and 6-Month outcomes over a period of 20 years in the FAST-MI program (French Registry of Acute ST-Elevation or Non-ST-Elevation myocardial infarction) 1995 to 2015. Circulation. 2017;136(20):1908\u201319. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.117.030798.","journal-title":"Circulation"},{"issue":"24","key":"7587_CR3","doi-asserted-by":"publisher","first-page":"e018897","DOI":"10.1161\/JAHA.120.018897","volume":"9","author":"BE Claessen","year":"2020","unstructured":"Claessen BE, Guedeney P, Gibson CM, et al. Lipid management in patients presenting with Acute Coronary syndromes: a review. J Am Heart Assoc. 2020;9(24):e018897. https:\/\/doi.org\/10.1161\/JAHA.120.018897.","journal-title":"J Am Heart Assoc"},{"issue":"3","key":"7587_CR4","doi-asserted-by":"publisher","first-page":"130","DOI":"10.4103\/cp.cp_20_20","volume":"5","author":"CMD Association","year":"2020","unstructured":"Association CMD. Expert consensus on clinical pathway of blood lipid management in patients with acute coronary syndrome. J Cardiol Plus. 2020;5(3):130.","journal-title":"J Cardiol Plus"},{"key":"7587_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijcard.2020.05.022","volume":"315","author":"Y Huo","year":"2020","unstructured":"Huo Y, Lee SW, Sawhney JPS, et al. Two-year outcomes post-discharge in Asian patients with acute coronary syndrome: findings from the EPICOR Asia study. Int J Cardiol. 2020;315:1\u20138. https:\/\/doi.org\/10.1016\/j.ijcard.2020.05.022.","journal-title":"Int J Cardiol"},{"issue":"9","key":"7587_CR6","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1002\/clc.22431","volume":"38","author":"Y Huo","year":"2015","unstructured":"Huo Y, Lee SW, Sawhney JP, et al. Rationale, design, and baseline characteristics of the EPICOR Asia Study (Long-tErm follow-uP of antithrombotic management patterns in Acute CORonary Syndrome patients in Asia). Clin Cardiol. 2015;38(9):511\u20139. https:\/\/doi.org\/10.1002\/clc.22431.","journal-title":"Clin Cardiol"},{"issue":"12","key":"7587_CR7","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1161\/CIRCRESAHA.114.302805","volume":"114","author":"RS Rosenson","year":"2014","unstructured":"Rosenson RS, Brewer HB, Rader DJ. Lipoproteins as biomarkers and therapeutic targets in the setting of acute coronary syndrome. Circ Res. 2014;114(12):1880\u20139. https:\/\/doi.org\/10.1161\/CIRCRESAHA.114.302805.","journal-title":"Circ Res"},{"issue":"1","key":"7587_CR8","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, et al. 2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111\u201388. https:\/\/doi.org\/10.1093\/eurheartj\/ehz455.","journal-title":"Eur Heart J"},{"issue":"4","key":"7587_CR9","doi-asserted-by":"publisher","first-page":"35","DOI":"10.5837\/bjc.2022.035","volume":"29","author":"Z Khan","year":"2022","unstructured":"Khan Z, Rakhit R. Secondary prevention lipid management following ACS: a missed opportunity? Br J Cardiol. 2022;29(4):35. https:\/\/doi.org\/10.5837\/bjc.2022.035.","journal-title":"Br J Cardiol"},{"issue":"9493","key":"7587_CR10","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","volume":"366","author":"C Baigent","year":"2005","unstructured":"Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267\u201378. https:\/\/doi.org\/10.1016\/S0140-6736(05)67394-1.","journal-title":"Lancet"},{"issue":"4","key":"7587_CR11","first-page":"227","volume":"17","author":"P Ostadal","year":"2012","unstructured":"Ostadal P. Statins as first-line therapy for acute coronary syndrome? Exp Clin Cardiol. 2012;17(4):227\u201336.","journal-title":"Exp Clin Cardiol"},{"issue":"14","key":"7587_CR12","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1056\/NEJM199610033351401","volume":"335","author":"FM Sacks","year":"1996","unstructured":"Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators. N Engl J Med. 1996;335(14):1001\u20139. https:\/\/doi.org\/10.1056\/NEJM199610033351401.","journal-title":"N Engl J Med"},{"issue":"20","key":"7587_CR13","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1001\/jama.279.20.1615","volume":"279","author":"JR Downs","year":"1998","unstructured":"Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS\/TexCAPS. Air Force\/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279(20):1615\u201322. https:\/\/doi.org\/10.1001\/jama.279.20.1615.","journal-title":"JAMA"},{"issue":"19","key":"7587_CR14","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1001\/jama.294.19.2437","volume":"294","author":"TR Pedersen","year":"2005","unstructured":"Pedersen TR, Faergeman O, Kastelein JJ, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA. 2005;294(19):2437\u201345. https:\/\/doi.org\/10.1001\/jama.294.19.2437.","journal-title":"JAMA"},{"issue":"14","key":"7587_CR15","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMoa050461","volume":"352","author":"JC LaRosa","year":"2005","unstructured":"LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352(14):1425\u201335. https:\/\/doi.org\/10.1056\/NEJMoa050461.","journal-title":"N Engl J Med"},{"issue":"2","key":"7587_CR16","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.jjcc.2017.02.004","volume":"70","author":"K Fujisue","year":"2017","unstructured":"Fujisue K, Tsujita K. Current status of lipid management in acute coronary syndrome. J Cardiol. 2017;70(2):101\u20136. https:\/\/doi.org\/10.1016\/j.jjcc.2017.02.004.","journal-title":"J Cardiol"},{"issue":"8","key":"7587_CR17","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/j.jacc.2005.03.077","volume":"46","author":"KK Ray","year":"2005","unstructured":"Ray KK, Cannon CP, McCabe CH, et al. Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial. J Am Coll Cardiol. 2005;46(8):1405\u201310. https:\/\/doi.org\/10.1016\/j.jacc.2005.03.077.","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"7587_CR18","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1016\/j.amjcard.2005.11.031","volume":"97","author":"T Sakamoto","year":"2006","unstructured":"Sakamoto T, Kojima S, Ogawa H, et al. Effects of early statin treatment on symptomatic heart failure and ischemic events after acute myocardial infarction in Japanese. Am J Cardiol. 2006;97(8):1165\u201371. https:\/\/doi.org\/10.1016\/j.amjcard.2005.11.031.","journal-title":"Am J Cardiol"},{"issue":"11","key":"7587_CR19","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1001\/jama.292.11.1307","volume":"292","author":"JA de Lemos","year":"2004","unstructured":"de Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA. 2004;292(11):1307\u201316. https:\/\/doi.org\/10.1001\/jama.292.11.1307.","journal-title":"JAMA"},{"issue":"15","key":"7587_CR20","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1056\/NEJMoa040583","volume":"350","author":"CP Cannon","year":"2004","unstructured":"Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350(15):1495\u2013504. https:\/\/doi.org\/10.1056\/NEJMoa040583.","journal-title":"N Engl J Med"},{"issue":"13","key":"7587_CR21","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1001\/jama.285.13.1711","volume":"285","author":"GG Schwartz","year":"2001","unstructured":"Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001;285(13):1711\u20138. https:\/\/doi.org\/10.1001\/jama.285.13.1711.","journal-title":"JAMA"},{"issue":"13","key":"7587_CR22","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1161\/01.CIR.0000091404.09558.AF","volume":"108","author":"S Kinlay","year":"2003","unstructured":"Kinlay S, Schwartz GG, Olsson AG, et al. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation. 2003;108(13):1560\u20136. https:\/\/doi.org\/10.1161\/01.CIR.0000091404.09558.AF.","journal-title":"Circulation"},{"issue":"3","key":"7587_CR23","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.ahj.2004.06.033","volume":"149","author":"CS Smith","year":"2005","unstructured":"Smith CS, Cannon CP, McCabe CH, et al. Early initiation of lipid-lowering therapy for acute coronary syndromes improves compliance with guideline recommendations: observations from the Orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial. Am Heart J. 2005;149(3):444\u201350. https:\/\/doi.org\/10.1016\/j.ahj.2004.06.033.","journal-title":"Am Heart J"},{"issue":"21","key":"7587_CR24","doi-asserted-by":"publisher","first-page":"2576","DOI":"10.1001\/archinte.163.21.2576","volume":"163","author":"HD Aronow","year":"2003","unstructured":"Aronow HD, Novaro GM, Lauer MS, et al. In-hospital initiation of lipid-lowering therapy after coronary intervention as a predictor of long-term utilization: a propensity analysis. Arch Intern Med. 2003;163(21):2576\u201382. https:\/\/doi.org\/10.1001\/archinte.163.21.2576.","journal-title":"Arch Intern Med"},{"issue":"12","key":"7587_CR25","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1016\/j.jacc.2007.02.025","volume":"49","author":"G Patti","year":"2007","unstructured":"Patti G, Pasceri V, Colonna G, et al. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. J Am Coll Cardiol. 2007;49(12):1272\u20138. https:\/\/doi.org\/10.1016\/j.jacc.2007.02.025.","journal-title":"J Am Coll Cardiol"},{"issue":"15","key":"7587_CR26","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1161\/CIRCULATIONAHA.110.002451","volume":"123","author":"G Patti","year":"2011","unstructured":"Patti G, Cannon CP, Murphy SA, et al. Clinical benefit of statin pretreatment in patients undergoing percutaneous coronary intervention: a collaborative patient-level meta-analysis of 13 randomized studies. Circulation. 2011;123(15):1622\u201332. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.110.002451.","journal-title":"Circulation"},{"issue":"10","key":"7587_CR27","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1016\/j.amjcard.2014.02.034","volume":"113","author":"EP Navarese","year":"2014","unstructured":"Navarese EP, Kowalewski M, Andreotti F, et al. Meta-analysis of time-related benefits of statin therapy in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Am J Cardiol. 2014;113(10):1753\u201364. https:\/\/doi.org\/10.1016\/j.amjcard.2014.02.034.","journal-title":"Am J Cardiol"},{"issue":"7","key":"7587_CR28","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1002\/clc.23410","volume":"43","author":"B Gencer","year":"2020","unstructured":"Gencer B, Giugliano RP. Management of LDL-cholesterol after an acute coronary syndrome: key comparisons of the American and European clinical guidelines to the attention of the healthcare providers. Clin Cardiol. 2020;43(7):684\u201390. https:\/\/doi.org\/10.1002\/clc.23410.","journal-title":"Clin Cardiol"},{"issue":"8","key":"7587_CR29","first-page":"665","volume":"44","author":"Y Li","year":"2016","unstructured":"Li Y, Zhao S, Ye P, et al. Status of cholesterol goal attainment for the primary and secondary prevention of atherosclerotic cardiovascular disease in dyslipidemia patients receiving lipid-lowering therapy: DYSIS-China subgroup analysis. J Zhonghua Xin Xue Guan Bing Za Zhi. 2016;44(8):665\u201370.","journal-title":"J Zhonghua Xin Xue Guan Bing Za Zhi"},{"issue":"17","key":"7587_CR30","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1093\/eurheartj\/eht055","volume":"34","author":"HTC Group","year":"2013","unstructured":"Group HTC. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin\/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J. 2013;34(17):1279\u201391. https:\/\/doi.org\/10.1093\/eurheartj\/eht055.","journal-title":"Eur Heart J"},{"key":"7587_CR31","first-page":"390","volume":"35","author":"Adults JCfDCgoPaToDi","year":"2007","unstructured":"Adults JCfDCgoPaToDi. Chinese guidelines on prevention and treatment of dyslipidemia in adults. J Zhonghua Xin Xue Guan Bing Za Zhi. 2007;35:390\u2013419.","journal-title":"J Zhonghua Xin Xue Guan Bing Za Zhi"},{"issue":"10059","key":"7587_CR32","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1016\/S0140-6736(16)31357-5","volume":"388","author":"R Collins","year":"2016","unstructured":"Collins R, Reith C, Emberson J, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016;388(10059):2532\u201361. https:\/\/doi.org\/10.1016\/S0140-6736(16)31357-5.","journal-title":"Lancet"},{"issue":"20","key":"7587_CR33","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1016\/j.jacc.2019.08.010","volume":"74","author":"KC Koskinas","year":"2019","unstructured":"Koskinas KC, Windecker S, Pedrazzini G, et al. Evolocumab for early reduction of LDL Cholesterol Levels in patients with Acute Coronary syndromes (EVOPACS). J Am Coll Cardiol. 2019;74(20):2452\u201362. https:\/\/doi.org\/10.1016\/j.jacc.2019.08.010.","journal-title":"J Am Coll Cardiol"},{"issue":"32","key":"7587_CR34","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1093\/eurheartj\/ehw628","volume":"38","author":"A Vonbank","year":"2017","unstructured":"Vonbank A, Agewall S, Kjeldsen KP, et al. Comprehensive efforts to increase adherence to statin therapy. Eur Heart J. 2017;38(32):2473\u20139. https:\/\/doi.org\/10.1093\/eurheartj\/ehw628.","journal-title":"Eur Heart J"},{"issue":"1","key":"7587_CR35","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.atherosclerosis.2014.12.049","volume":"239","author":"B Gencer","year":"2015","unstructured":"Gencer B, Auer R, Nanchen D, et al. Expected impact of applying new 2013 AHA\/ACC cholesterol guidelines criteria on the recommended lipid target achievement after acute coronary syndromes. Atherosclerosis. 2015;239(1):118\u201324. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2014.12.049.","journal-title":"Atherosclerosis"},{"issue":"3","key":"7587_CR36","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1002\/clc.22518","volume":"39","author":"SE Nissen","year":"2016","unstructured":"Nissen SE, Dent-Acosta RE, Rosenson RS, et al. Comparison of PCSK9 inhibitor evolocumab vs ezetimibe in statin-intolerant patients: design of the goal achievement after utilizing an Anti-PCSK9 antibody in statin-intolerant subjects 3 (GAUSS-3) trial. Clin Cardiol. 2016;39(3):137\u201344. https:\/\/doi.org\/10.1002\/clc.22518.","journal-title":"Clin Cardiol"},{"issue":"6","key":"7587_CR37","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s10557-005-5686-z","volume":"19","author":"E Bruckert","year":"2005","unstructured":"Bruckert E, Hayem G, Dejager S, Yau C, Begaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients\u2013the PRIMO study. Cardiovasc Drugs Ther. 2005;19(6):403\u201314. https:\/\/doi.org\/10.1007\/s10557-005-5686-z.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"7","key":"7587_CR38","doi-asserted-by":"publisher","first-page":"526","DOI":"10.7326\/0003-4819-158-7-201304020-00004","volume":"158","author":"H Zhang","year":"2013","unstructured":"Zhang H, Plutzky J, Skentzos S, et al. Discontinuation of statins in routine care settings: a cohort study. Ann Intern Med. 2013;158(7):526\u201334. https:\/\/doi.org\/10.7326\/0003-4819-158-7-201304020-00004.","journal-title":"Ann Intern Med"},{"issue":"8","key":"7587_CR39","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s11886-020-01326-w","volume":"22","author":"L Masana","year":"2020","unstructured":"Masana L, Ibarretxe D, Plana N. Reasons why Combination Therapy should be the New Standard of Care to achieve the LDL-Cholesterol targets: lipid-lowering combination therapy. Curr Cardiol Rep. 2020;22(8):66. https:\/\/doi.org\/10.1007\/s11886-020-01326-w.","journal-title":"Curr Cardiol Rep"},{"issue":"1","key":"7587_CR40","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.atherosclerosis.2015.03.002","volume":"240","author":"L Masana","year":"2015","unstructured":"Masana L, Pedro-Botet J, Civeira F. IMPROVE-IT clinical implications. Should the high-intensity cholesterol-lowering therapy strategy replace the high-intensity statin therapy? Atherosclerosis. 2015;240(1):161\u20132. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2015.03.002.","journal-title":"Atherosclerosis"},{"issue":"8","key":"7587_CR41","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1001\/jamacardio.2017.0911","volume":"2","author":"LD Colantonio","year":"2017","unstructured":"Colantonio LD, Huang L, Monda KL, et al. Adherence to high-intensity statins following a myocardial infarction hospitalization among Medicare beneficiaries. JAMA Cardiol. 2017;2(8):890\u20135. https:\/\/doi.org\/10.1001\/jamacardio.2017.0911.","journal-title":"JAMA Cardiol"},{"key":"7587_CR42","doi-asserted-by":"publisher","first-page":"547","DOI":"10.2147\/CLEP.S400903","volume":"15","author":"R Khatib","year":"2023","unstructured":"Khatib R, Yeh EJ, Glowacki N, et al. Lipid-lowering therapy utilization and dosage among patients with Acute Coronary syndrome events: a retrospective cohort from 12 community hospitals. Clin Epidemiol. 2023;15:547\u201357. https:\/\/doi.org\/10.2147\/CLEP.S400903.","journal-title":"Clin Epidemiol"},{"issue":"5","key":"7587_CR43","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.jacl.2008.06.011","volume":"2","author":"PP Toth","year":"2008","unstructured":"Toth PP, Maki KC. A commentary on the implications of the ENHANCE (Ezetimibe and Simvastatin in Hypercholesterolemia enhances atherosclerosis regression) trial: should ezetimibe move to the Back of the line as a therapy for dyslipidemia? J Clin Lipidol. 2008;2(5):313\u20137. https:\/\/doi.org\/10.1016\/j.jacl.2008.06.011.","journal-title":"J Clin Lipidol"},{"issue":"25","key":"7587_CR44","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","volume":"372","author":"CP Cannon","year":"2015","unstructured":"Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after Acute Coronary syndromes. N Engl J Med. 2015;372(25):2387\u201397. https:\/\/doi.org\/10.1056\/NEJMoa1410489.","journal-title":"N Engl J Med"},{"issue":"4","key":"7587_CR45","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.jacc.2015.10.077","volume":"67","author":"SA Murphy","year":"2016","unstructured":"Murphy SA, Cannon CP, Blazing MA, et al. Reduction in Total Cardiovascular events with Ezetimibe\/Simvastatin Post-acute Coronary Syndrome: the IMPROVE-IT Trial. J Am Coll Cardiol. 2016;67(4):353\u201361. https:\/\/doi.org\/10.1016\/j.jacc.2015.10.077.","journal-title":"J Am Coll Cardiol"},{"issue":"13","key":"7587_CR46","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1161\/CIRCULATIONAHA.115.018381","volume":"132","author":"EA Bohula","year":"2015","unstructured":"Bohula EA, Giugliano RP, Cannon CP, et al. Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT. Circulation. 2015;132(13):1224\u201333. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.115.018381.","journal-title":"Circulation"},{"issue":"5","key":"7587_CR47","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1001\/jamacardio.2017.0083","volume":"2","author":"RP Giugliano","year":"2017","unstructured":"Giugliano RP, Wiviott SD, Blazing MA, et al. Long-term safety and efficacy of achieving very low levels of low-density lipoprotein cholesterol: a prespecified analysis of the IMPROVE-IT Trial. JAMA Cardiol. 2017;2(5):547\u201355. https:\/\/doi.org\/10.1001\/jamacardio.2017.0083.","journal-title":"JAMA Cardiol"},{"issue":"15","key":"7587_CR48","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1161\/CIRCULATIONAHA.117.030950","volume":"137","author":"RP Giugliano","year":"2018","unstructured":"Giugliano RP, Cannon CP, Blazing MA, et al. Benefit of adding Ezetimibe to Statin Therapy on Cardiovascular outcomes and Safety in patients with Versus without Diabetes Mellitus: results from IMPROVE-IT (improved reduction of outcomes: Vytorin Efficacy International Trial). Circulation. 2018;137(15):1571\u201382. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.117.030950.","journal-title":"Circulation"},{"issue":"9","key":"7587_CR49","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1001\/jamacardio.2019.2306","volume":"4","author":"RG Bach","year":"2019","unstructured":"Bach RG, Cannon CP, Giugliano RP, et al. Effect of simvastatin-ezetimibe compared with simvastatin Monotherapy after Acute Coronary Syndrome among patients 75 years or older: a secondary analysis of a Randomized Clinical Trial. JAMA Cardiol. 2019;4(9):846\u201354. https:\/\/doi.org\/10.1001\/jamacardio.2019.2306.","journal-title":"JAMA Cardiol"},{"issue":"5","key":"7587_CR50","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.jacc.2015.05.065","volume":"66","author":"K Tsujita","year":"2015","unstructured":"Tsujita K, Sugiyama S, Sumida H, et al. Impact of dual lipid-lowering Strategy with Ezetimibe and Atorvastatin on Coronary Plaque regression in patients with percutaneous coronary intervention: the Multicenter Randomized Controlled PRECISE-IVUS Trial. J Am Coll Cardiol. 2015;66(5):495\u2013507. https:\/\/doi.org\/10.1016\/j.jacc.2015.05.065.","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"7587_CR51","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1093\/eurheartj\/ehac709","volume":"44","author":"YJ Lee","year":"2023","unstructured":"Lee YJ, Cho JY, You SC, et al. Moderate-intensity statin with ezetimibe vs. high-intensity statin in patients with diabetes and atherosclerotic cardiovascular disease in the RACING trial. Eur Heart J. 2023;44(11):972\u201383. https:\/\/doi.org\/10.1093\/eurheartj\/ehac709.","journal-title":"Eur Heart J"},{"key":"7587_CR52","doi-asserted-by":"publisher","first-page":"110388","DOI":"10.1016\/j.biopha.2020.110388","volume":"129","author":"M Niedzielski","year":"2020","unstructured":"Niedzielski M, Broncel M, Gorzelak-Pabis P, Wozniak E. New possible pharmacological targets for statins and ezetimibe. Biomed Pharmacother. 2020;129:110388. https:\/\/doi.org\/10.1016\/j.biopha.2020.110388.","journal-title":"Biomed Pharmacother"},{"issue":"8","key":"7587_CR53","doi-asserted-by":"publisher","first-page":"2810","DOI":"10.1210\/en.2013-2143","volume":"155","author":"T Sugizaki","year":"2014","unstructured":"Sugizaki T, Watanabe M, Horai Y, et al. The Niemann-pick C1 like 1 (NPC1L1) inhibitor ezetimibe improves metabolic disease via decreased liver X receptor (LXR) activity in liver of obese male mice. Endocrinology. 2014;155(8):2810\u20139. https:\/\/doi.org\/10.1210\/en.2013-2143.","journal-title":"Endocrinology"},{"key":"7587_CR54","doi-asserted-by":"publisher","unstructured":"Cho Y, Kim RH, Park H, Wang HJ, Lee H, Kang ES. Effect of ezetimibe on glucose metabolism and inflammatory markers in adipose tissue. Biomedicines. 2020;8(11):512. https:\/\/doi.org\/10.3390\/biomedicines8110512.","DOI":"10.3390\/biomedicines8110512"},{"issue":"2","key":"7587_CR55","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.atherosclerosis.2012.08.037","volume":"225","author":"E Moutzouri","year":"2012","unstructured":"Moutzouri E, Tellis CC, Rousouli K, et al. Effect of simvastatin or its combination with ezetimibe on toll-like receptor expression and lipopolysaccharide - induced cytokine production in monocytes of hypercholesterolemic patients. Atherosclerosis. 2012;225(2):381\u20137. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2012.08.037.","journal-title":"Atherosclerosis"},{"issue":"1","key":"7587_CR56","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.atherosclerosis.2014.08.038","volume":"237","author":"TP Leren","year":"2014","unstructured":"Leren TP. Sorting an LDL receptor with bound PCSK9 to intracellular degradation. Atherosclerosis. 2014;237(1):76\u201381. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2014.08.038.","journal-title":"Atherosclerosis"},{"issue":"11","key":"7587_CR57","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.numecd.2011.06.002","volume":"21","author":"G Tibolla","year":"2011","unstructured":"Tibolla G, Norata GD, Artali R, Meneghetti F, Catapano AL. Proprotein convertase subtilisin\/kexin type 9 (PCSK9): from structure-function relation to therapeutic inhibition. Nutr Metab Cardiovasc Dis. 2011;21(11):835\u201343. https:\/\/doi.org\/10.1016\/j.numecd.2011.06.002.","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"3","key":"7587_CR58","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s40292-019-00323-7","volume":"26","author":"R Del Pinto","year":"2019","unstructured":"Del Pinto R, Grassi D, Properzi G, Desideri G, Ferri C. Low Density Lipoprotein (LDL) cholesterol as a causal role for atherosclerotic disease: potential role of PCSK9 inhibitors. High Blood Press Cardiovasc Prev. 2019;26(3):199\u2013207. https:\/\/doi.org\/10.1007\/s40292-019-00323-7.","journal-title":"High Blood Press Cardiovasc Prev"},{"issue":"1","key":"7587_CR59","doi-asserted-by":"publisher","first-page":"40","DOI":"10.7326\/M14-2957","volume":"163","author":"EP Navarese","year":"2015","unstructured":"Navarese EP, Kolodziejczak M, Schulze V, et al. Effects of Proprotein Convertase Subtilisin\/Kexin Type 9 Antibodies in adults with hypercholesterolemia: a systematic review and Meta-analysis. Ann Intern Med. 2015;163(1):40\u201351. https:\/\/doi.org\/10.7326\/M14-2957.","journal-title":"Ann Intern Med"},{"issue":"22","key":"7587_CR60","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","volume":"379","author":"GG Schwartz","year":"2018","unstructured":"Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and Cardiovascular outcomes after Acute Coronary Syndrome. N Engl J Med. 2018;379(22):2097\u2013107. https:\/\/doi.org\/10.1056\/NEJMoa1801174.","journal-title":"N Engl J Med"},{"issue":"4","key":"7587_CR61","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.jacc.2018.10.039","volume":"73","author":"M Szarek","year":"2019","unstructured":"Szarek M, White HD, Schwartz GG, et al. Alirocumab Reduces Total Nonfatal Cardiovascular and fatal events: the ODYSSEY OUTCOMES trial. J Am Coll Cardiol. 2019;73(4):387\u201396. https:\/\/doi.org\/10.1016\/j.jacc.2018.10.039.","journal-title":"J Am Coll Cardiol"},{"issue":"25","key":"7587_CR62","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1161\/CIRCULATIONAHA.119.043826","volume":"140","author":"JW Jukema","year":"2019","unstructured":"Jukema JW, Zijlstra LE, Bhatt DL, et al. Effect of Alirocumab on Stroke in ODYSSEY OUTCOMES. Circulation. 2019;140(25):2054\u201362. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.119.043826.","journal-title":"Circulation"},{"issue":"20","key":"7587_CR63","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1161\/CIRCULATIONAHA.120.046524","volume":"141","author":"GG Schwartz","year":"2020","unstructured":"Schwartz GG, Steg PG, Szarek M, et al. Peripheral artery disease and venous thromboembolic events after Acute Coronary Syndrome: role of lipoprotein(a) and modification by Alirocumab: Prespecified Analysis of the ODYSSEY OUTCOMES randomized clinical trial. Circulation. 2020;141(20):1608\u201317. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.046524.","journal-title":"Circulation"},{"issue":"18","key":"7587_CR64","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and Clinical outcomes in patients with Cardiovascular Disease. N Engl J Med. 2017;376(18):1713\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1615664.","journal-title":"N Engl J Med"},{"issue":"2","key":"7587_CR65","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1001\/jamacardio.2020.3151","volume":"6","author":"P Deedwania","year":"2021","unstructured":"Deedwania P, Murphy SA, Scheen A, et al. Efficacy and safety of PCSK9 inhibition with Evolocumab in reducing Cardiovascular events in patients with metabolic syndrome receiving statin therapy: secondary analysis from the FOURIER Randomized Clinical Trial. JAMA Cardiol. 2021;6(2):139\u201347. https:\/\/doi.org\/10.1001\/jamacardio.2020.3151.","journal-title":"JAMA Cardiol"},{"issue":"3","key":"7587_CR66","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1097\/FJC.0000000000000706","volume":"74","author":"CR Trankle","year":"2019","unstructured":"Trankle CR, Wohlford G, Buckley LF, et al. Alirocumab in Acute myocardial infarction: results from the Virginia Commonwealth University Alirocumab Response Trial (VCU-AlirocRT). J Cardiovasc Pharmacol. 2019;74(3):266\u20139. https:\/\/doi.org\/10.1097\/FJC.0000000000000706.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"11","key":"7587_CR67","doi-asserted-by":"publisher","first-page":"e888","DOI":"10.4244\/EIJ-D-22-00735","volume":"18","author":"SR Mehta","year":"2022","unstructured":"Mehta SR, Pare G, Lonn EM, et al. Effects of routine early treatment with PCSK9 inhibitors in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: a randomised, double-blind, sham-controlled trial. EuroIntervention. 2022;18(11):e888\u201396. https:\/\/doi.org\/10.4244\/EIJ-D-22-00735.","journal-title":"EuroIntervention"},{"issue":"12","key":"7587_CR68","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1002\/clc.23112","volume":"41","author":"KC Koskinas","year":"2018","unstructured":"Koskinas KC, Windecker S, Buhayer A, et al. Design of the randomized, placebo-controlled evolocumab for early reduction of LDL-cholesterol levels in patients with acute coronary syndromes (EVOPACS) trial. Clin Cardiol. 2018;41(12):1513\u201320. https:\/\/doi.org\/10.1002\/clc.23112.","journal-title":"Clin Cardiol"},{"issue":"4","key":"7587_CR69","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1161\/CIRCULATIONAHA.120.046320","volume":"142","author":"TM Leucker","year":"2020","unstructured":"Leucker TM, Blaha MJ, Jones SR, et al. Effect of Evolocumab on atherogenic lipoproteins during the Peri- and early postinfarction period: a Placebo-Controlled, Randomized Trial. Circulation. 2020;142(4):419\u201321. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.046320.","journal-title":"Circulation"},{"issue":"18","key":"7587_CR70","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1001\/jama.2022.5218","volume":"327","author":"L Raber","year":"2022","unstructured":"Raber L, Ueki Y, Otsuka T, et al. Effect of Alirocumab added to high-intensity statin therapy on coronary atherosclerosis in patients with Acute myocardial infarction: the PACMAN-AMI Randomized Clinical Trial. JAMA. 2022;327(18):1771\u201381. https:\/\/doi.org\/10.1001\/jama.2022.5218.","journal-title":"JAMA"},{"issue":"3","key":"7587_CR71","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.jjcc.2019.08.002","volume":"75","author":"H Yano","year":"2020","unstructured":"Yano H, Horinaka S, Ishimitsu T. Effect of evolocumab therapy on coronary fibrous cap thickness assessed by optical coherence tomography in patients with acute coronary syndrome. J Cardiol. 2020;75(3):289\u201395. https:\/\/doi.org\/10.1016\/j.jjcc.2019.08.002.","journal-title":"J Cardiol"},{"issue":"6","key":"7587_CR72","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.diabet.2017.07.009","volume":"43","author":"B Cariou","year":"2017","unstructured":"Cariou B, Guerin P, Le May C, et al. Circulating PCSK9 levels in acute coronary syndrome: results from the PC-SCA-9 prospective study. Diabetes Metab. 2017;43(6):529\u201335. https:\/\/doi.org\/10.1016\/j.diabet.2017.07.009.","journal-title":"Diabetes Metab"},{"issue":"6","key":"7587_CR73","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1093\/eurheartj\/ehv637","volume":"37","author":"B Gencer","year":"2016","unstructured":"Gencer B, Montecucco F, Nanchen D, et al. Prognostic value of PCSK9 levels in patients with acute coronary syndromes. Eur Heart J. 2016;37(6):546\u201353. https:\/\/doi.org\/10.1093\/eurheartj\/ehv637.","journal-title":"Eur Heart J"},{"key":"7587_CR74","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1186\/1471-2261-14-192","volume":"14","author":"Y Zhang","year":"2014","unstructured":"Zhang Y, Liu J, Li S, et al. Proprotein convertase subtilisin\/kexin type 9 expression is transiently up-regulated in the acute period of myocardial infarction in rat. BMC Cardiovasc Disord. 2014;14:192. https:\/\/doi.org\/10.1186\/1471-2261-14-192.","journal-title":"BMC Cardiovasc Disord"},{"issue":"4","key":"7587_CR75","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s11883-018-0718-x","volume":"20","author":"AD Karagiannis","year":"2018","unstructured":"Karagiannis AD, Liu M, Toth PP, et al. Pleiotropic anti-atherosclerotic effects of PCSK9 InhibitorsFrom Molecular Biology to Clinical Translation. Curr Atheroscler Rep. 2018;20(4):20. https:\/\/doi.org\/10.1007\/s11883-018-0718-x.","journal-title":"Curr Atheroscler Rep"},{"key":"7587_CR76","doi-asserted-by":"publisher","first-page":"3179201","DOI":"10.1155\/2018\/3179201","volume":"2018","author":"D Bandyopadhyay","year":"2018","unstructured":"Bandyopadhyay D, Ashish K, Hajra A, Qureshi A, Ghosh RK. Cardiovascular outcomes of PCSK9 inhibitors: with special emphasis on its effect beyond LDL-Cholesterol lowering. J Lipids. 2018;2018:3179201. https:\/\/doi.org\/10.1155\/2018\/3179201.","journal-title":"J Lipids"},{"issue":"22","key":"7587_CR77","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1161\/CIRCULATIONAHA.116.023687","volume":"134","author":"V Bittner","year":"2016","unstructured":"Bittner V. Pleiotropic effects of PCSK9 (Proprotein Convertase Subtilisin\/Kexin type 9) inhibitors? Circulation. 2016;134(22):1695\u20136. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.116.023687.","journal-title":"Circulation"},{"issue":"6","key":"7587_CR78","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1097\/SHK.0000000000000682","volume":"46","author":"DJ Dwivedi","year":"2016","unstructured":"Dwivedi DJ, Grin PM, Khan M, et al. Differential expression of PCSK9 modulates infection, inflammation, and Coagulation in a murine model of Sepsis. Shock. 2016;46(6):672\u201380. https:\/\/doi.org\/10.1097\/SHK.0000000000000682.","journal-title":"Shock"},{"issue":"5","key":"7587_CR79","doi-asserted-by":"publisher","first-page":"e63746","DOI":"10.1371\/journal.pone.0063746","volume":"8","author":"HY Cheng","year":"2013","unstructured":"Cheng HY, Wu R, Gebre AK, et al. Increased cholesterol content in gammadelta (gammadelta) T lymphocytes differentially regulates their activation. PLoS ONE. 2013;8(5):e63746. https:\/\/doi.org\/10.1371\/journal.pone.0063746.","journal-title":"PLoS ONE"},{"issue":"1","key":"7587_CR80","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1038\/s41598-018-20425-x","volume":"8","author":"C Ricci","year":"2018","unstructured":"Ricci C, Ruscica M, Camera M, et al. PCSK9 induces a pro-inflammatory response in macrophages. Sci Rep. 2018;8(1):2267. https:\/\/doi.org\/10.1038\/s41598-018-20425-x.","journal-title":"Sci Rep"},{"issue":"10","key":"7587_CR81","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1194\/jlr.M051326","volume":"55","author":"S Kuhnast","year":"2014","unstructured":"Kuhnast S, van der Hoorn JW, Pieterman EJ, et al. Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin. J Lipid Res. 2014;55(10):2103\u201312. https:\/\/doi.org\/10.1194\/jlr.M051326.","journal-title":"J Lipid Res"},{"issue":"4","key":"7587_CR82","doi-asserted-by":"publisher","first-page":"931","DOI":"10.3892\/ijmm.2012.1072","volume":"30","author":"Z Tang","year":"2012","unstructured":"Tang Z, Jiang L, Peng J, et al. PCSK9 siRNA suppresses the inflammatory response induced by oxLDL through inhibition of NF-kappaB activation in THP-1-derived macrophages. Int J Mol Med. 2012;30(4):931\u20138. https:\/\/doi.org\/10.3892\/ijmm.2012.1072.","journal-title":"Int J Mol Med"},{"key":"7587_CR83","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.atherosclerosis.2017.04.023","volume":"262","author":"ZH Tang","year":"2017","unstructured":"Tang ZH, Peng J, Ren Z, et al. New role of PCSK9 in atherosclerotic inflammation promotion involving the TLR4\/NF-kappaB pathway. Atherosclerosis. 2017;262:113\u201322. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2017.04.023.","journal-title":"Atherosclerosis"},{"key":"7587_CR84","doi-asserted-by":"publisher","unstructured":"Rehues P, Girona J, Guardiola M, Plana N, Scicali R, Piro S, Mu\u00f1iz-Grijalvo O, D\u00edaz-D\u00edaz JL, Recasens L, Pinyol M, Rosales R, Esteban Y, Amig\u00f3 N, Masana L, Ibarretxe D, Ribalta J. PCSK9 inhibitors have apolipoprotein C-III-related anti-inflammatory activity, assessed by 1H-NMR glycoprotein profile in subjects at high or very high cardiovascular risk. Int J Mol Sci. 2023;24(3):2319. https:\/\/doi.org\/10.3390\/ijms24032319.","DOI":"10.3390\/ijms24032319"},{"key":"7587_CR85","doi-asserted-by":"publisher","first-page":"117180","DOI":"10.1016\/j.atherosclerosis.2023.06.971","volume":"378","author":"R Marfella","year":"2023","unstructured":"Marfella R, Prattichizzo F, Sardu C, et al. Evidence of an anti-inflammatory effect of PCSK9 inhibitors within the human atherosclerotic plaque. Atherosclerosis. 2023;378:117180. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2023.06.971.","journal-title":"Atherosclerosis"},{"issue":"2","key":"7587_CR86","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.numecd.2019.09.012","volume":"30","author":"C Barale","year":"2020","unstructured":"Barale C, Bonomo K, Frascaroli C, et al. Platelet function and activation markers in primary hypercholesterolemia treated with anti-PCSK9 monoclonal antibody: a 12-month follow-up. Nutr Metab Cardiovasc Dis. 2020;30(2):282\u201391. https:\/\/doi.org\/10.1016\/j.numecd.2019.09.012.","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"7","key":"7587_CR87","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1016\/j.jcmg.2022.03.002","volume":"15","author":"SJ Nicholls","year":"2022","unstructured":"Nicholls SJ, Kataoka Y, Nissen SE, et al. Effect of Evolocumab on Coronary Plaque phenotype and burden in statin-treated patients following myocardial infarction. JACC Cardiovasc Imaging. 2022;15(7):1308\u201321. https:\/\/doi.org\/10.1016\/j.jcmg.2022.03.002.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"8","key":"7587_CR88","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1177\/2047487318766612","volume":"25","author":"SU Khan","year":"2018","unstructured":"Khan SU, Talluri S, Riaz H, et al. A bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular outcomes. Eur J Prev Cardiol. 2018;25(8):844\u201353. https:\/\/doi.org\/10.1177\/2047487318766612.","journal-title":"Eur J Prev Cardiol"},{"issue":"6","key":"7587_CR89","doi-asserted-by":"publisher","first-page":"e14400","DOI":"10.1097\/MD.0000000000014400","volume":"98","author":"Z Zhao","year":"2019","unstructured":"Zhao Z, Du S, Shen S, et al. Comparative efficacy and safety of lipid-lowering agents in patients with hypercholesterolemia: a frequentist network meta-analysis. Med (Baltim). 2019;98(6):e14400. https:\/\/doi.org\/10.1097\/MD.0000000000014400.","journal-title":"Med (Baltim)"},{"issue":"1","key":"7587_CR90","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1056\/NEJMp1614154","volume":"376","author":"A Khvorova","year":"2017","unstructured":"Khvorova A. Oligonucleotide therapeutics - a new class of cholesterol-lowering drugs. N Engl J Med. 2017;376(1):4\u20137. https:\/\/doi.org\/10.1056\/NEJMp1614154.","journal-title":"N Engl J Med"},{"issue":"24","key":"7587_CR91","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1016\/j.jacc.2023.10.007","volume":"82","author":"RS Wright","year":"2023","unstructured":"Wright RS, Koenig W, Landmesser U, et al. Safety and Tolerability of Inclisiran for treatment of Hypercholesterolemia in 7 clinical trials. J Am Coll Cardiol. 2023;82(24):2251\u201361. https:\/\/doi.org\/10.1016\/j.jacc.2023.10.007.","journal-title":"J Am Coll Cardiol"},{"issue":"15","key":"7587_CR92","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1056\/NEJMoa1615758","volume":"376","author":"KK Ray","year":"2017","unstructured":"Ray KK, Landmesser U, Leiter LA, et al. Inclisiran in patients at High Cardiovascular risk with elevated LDL cholesterol. N Engl J Med. 2017;376(15):1430\u201340. https:\/\/doi.org\/10.1056\/NEJMoa1615758.","journal-title":"N Engl J Med"},{"issue":"16","key":"7587_CR93","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1056\/NEJMoa1913805","volume":"382","author":"FJ Raal","year":"2020","unstructured":"Raal FJ, Kallend D, Ray KK, et al. Inclisiran for the treatment of heterozygous familial hypercholesterolemia. N Engl J Med. 2020;382(16):1520\u201330. https:\/\/doi.org\/10.1056\/NEJMoa1913805.","journal-title":"N Engl J Med"},{"issue":"16","key":"7587_CR94","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","volume":"382","author":"KK Ray","year":"2020","unstructured":"Ray KK, Wright RS, Kallend D, et al. Two phase 3 trials of Inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020;382(16):1507\u201319. https:\/\/doi.org\/10.1056\/NEJMoa1912387.","journal-title":"N Engl J Med"},{"issue":"9","key":"7587_CR95","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1007\/s40273-020-00948-w","volume":"38","author":"N Kam","year":"2020","unstructured":"Kam N, Perera K, Zomer E, Liew D, Ademi Z. Inclisiran as Adjunct lipid-lowering therapy for patients with Cardiovascular Disease: a cost-effectiveness analysis. PharmacoEconomics. 2020;38(9):1007\u201320. https:\/\/doi.org\/10.1007\/s40273-020-00948-w.","journal-title":"PharmacoEconomics"},{"key":"7587_CR96","unstructured":"A randomized trial assessing the effects of inclisiran on clinical outcomes among people with cardiovascular disease (ORION-4). ClinicalTrials.gov. University of Oxford. https:\/\/clinicaltrials.gov\/study\/NCT03705234"},{"issue":"10","key":"7587_CR97","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s11883-016-0611-4","volume":"18","author":"O Bilen","year":"2016","unstructured":"Bilen O, Ballantyne CM. Bempedoic Acid (ETC-1002): an investigational inhibitor of ATP citrate lyase. Curr Atheroscler Rep. 2016;18(10):61. https:\/\/doi.org\/10.1007\/s11883-016-0611-4.","journal-title":"Curr Atheroscler Rep"},{"issue":"11","key":"7587_CR98","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1056\/NEJMoa1803917","volume":"380","author":"KK Ray","year":"2019","unstructured":"Ray KK, Bays HE, Catapano AL, et al. Safety and Efficacy of Bempedoic Acid to reduce LDL cholesterol. N Engl J Med. 2019;380(11):1022\u201332. https:\/\/doi.org\/10.1056\/NEJMoa1803917.","journal-title":"N Engl J Med"},{"issue":"18","key":"7587_CR99","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1001\/jama.2019.16585","volume":"322","author":"AC Goldberg","year":"2019","unstructured":"Goldberg AC, Leiter LA, Stroes ESG, et al. Effect of Bempedoic Acid vs Placebo added to maximally tolerated statins on Low-Density Lipoprotein Cholesterol in patients at High Risk for Cardiovascular Disease: the CLEAR Wisdom Randomized Clinical Trial. JAMA. 2019;322(18):1780\u20138. https:\/\/doi.org\/10.1001\/jama.2019.16585.","journal-title":"JAMA"},{"issue":"6","key":"7587_CR100","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1177\/2047487319864671","volume":"27","author":"CM Ballantyne","year":"2020","unstructured":"Ballantyne CM, Laufs U, Ray KK, et al. Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy. Eur J Prev Cardiol. 2020;27(6):593\u2013603. https:\/\/doi.org\/10.1177\/2047487319864671.","journal-title":"Eur J Prev Cardiol"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-024-07587-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-024-07587-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-024-07587-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T07:00:55Z","timestamp":1766127655000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-024-07587-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,29]]},"references-count":100,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["7587"],"URL":"https:\/\/doi.org\/10.1007\/s10557-024-07587-9","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,29]]},"assertion":[{"value":"21 May 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"We did not provide the ethics approval because only the published data were included.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Publish"}},{"value":"The authors have no competing interests to declare that are relevant to the content of this article.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interest"}}]}}